Monograph

SDL subsidy will apply for all registered indications of infliximab biosimilar 100 mg vial (Remsima and Ixifi) in Singapore:

• Adults with moderately to severely active rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, ulcerative colitis or Crohn’s disease;
• Children aged 6 years or older with severe active Crohn’s disease; and
• Children aged 6 years or older with moderately to severely active ulcerative colitis.

SDL subsidy does not apply to proprietary infliximab 100 mg vial (Remicade) or other brands of infliximab biosimilars.

The Ministry of Health’s Drug Advisory Committee has not recommended subcutaneous infliximab biosimilar (Remsima) for inclusion on the MOH List of Subsidised Drugs for treating rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, Crohn’s disease, and ulcerative colitis. The decision was based on unacceptable pricing proposal from the company.

The Ministry of Health’s Drug Advisory Committee has not recommended listing vedolizumab on the Medication Assistance Fund (MAF) for treating ulcerative colitis and Crohn’s disease because of unacceptable cost-effectiveness compared with biosimilar infliximab at the price proposed by the manufacturer.